{"success":true,"data":{"pressRelease":{"id":"165423","rtpr_id":"nGNX5GG0DM-20261009","ticker":"RPRX","exchange":"NASDAQ","all_tickers":["RPRX"],"title":"Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026","author":"Globe Newswire","published_at":"2026-10-09T12:50:00.078Z","article_body":"NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX)\ntoday announced that it will report its third quarter 2026 financial results\non Wednesday, November 4, 2026 before the U.S. financial markets open. The\ncompany will host a conference call and simultaneous webcast at 8:00 a.m.\nEastern Time that day.\n\nConference Call Information\n\nPlease visit the “Investors” page of the company’s website at\nhttps://www.royaltypharma.com/investors/events/ to obtain conference call\ninformation and to view the live webcast. A replay of the conference call and\nwebcast will be archived on the company's website for at least 30 days.\n\nAbout Royalty Pharma plc\n\nFounded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical\nroyalties and a leading funder of innovation across the biopharmaceutical\nindustry, collaborating with innovators from academic institutions, research\nhospitals and non-profits through small and mid-cap biotechnology companies to\nleading global pharmaceutical companies. Royalty Pharma has assembled a\nportfolio of royalties which entitles it to payments based directly on the\ntop-line sales of many of the industry’s leading therapies. Royalty Pharma\nfunds innovation in the biopharmaceutical industry both directly and\nindirectly – directly when it partners with companies to co fund late-stage\nclinical trials and new product launches in exchange for future royalties, and\nindirectly when it acquires existing royalties from the original innovators.\nRoyalty Pharma’s current portfolio includes royalties on more than 35\ncommercial products, including Vertex’s Trikafta and Alyftrek, GSK’s\nTrelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri\nand Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s\nImbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and\nGilead’s Trodelvy, and 17 development-stage product candidates. For more\ninformation, visit www.royaltypharma.com. \n\nRoyalty Pharma Investor Relations and Communications\n\n+1 (212) 883-6772\nir@royaltypharma.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d605b3b0-7ba0-46e1-a2d4-439ca98694f8)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5GG0DM-20261009","title":"Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026","author":"Globe Newswire","ticker":"RPRX","created":"2026-10-09T12:50:00.078Z","tickers":["RPRX"],"exchange":"NASDAQ","article_body":"NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX)\ntoday announced that it will report its third quarter 2026 financial results\non Wednesday, November 4, 2026 before the U.S. financial markets open. The\ncompany will host a conference call and simultaneous webcast at 8:00 a.m.\nEastern Time that day.\n\nConference Call Information\n\nPlease visit the “Investors” page of the company’s website at\nhttps://www.royaltypharma.com/investors/events/ to obtain conference call\ninformation and to view the live webcast. A replay of the conference call and\nwebcast will be archived on the company's website for at least 30 days.\n\nAbout Royalty Pharma plc\n\nFounded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical\nroyalties and a leading funder of innovation across the biopharmaceutical\nindustry, collaborating with innovators from academic institutions, research\nhospitals and non-profits through small and mid-cap biotechnology companies to\nleading global pharmaceutical companies. Royalty Pharma has assembled a\nportfolio of royalties which entitles it to payments based directly on the\ntop-line sales of many of the industry’s leading therapies. Royalty Pharma\nfunds innovation in the biopharmaceutical industry both directly and\nindirectly – directly when it partners with companies to co fund late-stage\nclinical trials and new product launches in exchange for future royalties, and\nindirectly when it acquires existing royalties from the original innovators.\nRoyalty Pharma’s current portfolio includes royalties on more than 35\ncommercial products, including Vertex’s Trikafta and Alyftrek, GSK’s\nTrelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri\nand Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s\nImbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and\nGilead’s Trodelvy, and 17 development-stage product candidates. For more\ninformation, visit www.royaltypharma.com. \n\nRoyalty Pharma Investor Relations and Communications\n\n+1 (212) 883-6772\nir@royaltypharma.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d605b3b0-7ba0-46e1-a2d4-439ca98694f8)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-09T12:50:00.111334048Z","server_sent_at_ms":1791550200111},"received_at":"2026-10-09T12:50:00.161Z","source_url":null},"analysis":{"id":"153817","press_release_id":"165423","analysis_json":{"industry":{"label":"Financial Exchanges & Data","sector":"Financials"},"redFlags":[],"eventType":"other","narrative":"Royalty Pharma will report third quarter 2026 financial results on Wednesday, November 4, 2026 before U.S. markets open.\n\nA conference call and webcast will be held at 8:00 a.m. Eastern Time that day, with a replay archived for at least 30 days on the company's website.\n\nThis is a scheduling notice only; no results or guidance were included.\n\nRoyalty Pharma is the largest buyer of biopharmaceutical royalties with royalties on more than 35 commercial products including Vertex's Trikafta and GSK's Trelegy.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar item: RPRX Q3 2026 results due November 4, 2026 pre-market."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[],"products":["Trikafta","Alyftrek","Trelegy","Evrysdi","Tremfya","Tysabri","Spinraza","Voranigo","Imbruvica","Xtandi","Nurtec ODT","Trodelvy"],"companies":[{"name":"Royalty Pharma plc","ticker":"RPRX","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a routine earnings-date scheduling notice with no results, guidance, or financial figures. Boilerplate announcement of when Q3 2026 results will be released."},"tickerRelevance":{"others":[],"primary":"RPRX"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"earnings-date-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Royalty Pharma will report third quarter 2026 financial results on Wednesday, November 4, 2026 before U.S. markets open.\n\nA conference call and webcast will be held at 8:00 a.m. Eastern Time that day, with a replay archived for at least 30 days on the company's website.\n\nThis is a scheduling notice only; no results or guidance were included.\n\nRoyalty Pharma is the largest buyer of biopharmaceutical royalties with royalties on more than 35 commercial products including Vertex's Trikafta and GSK's Trelegy.","key_figures":{},"named_entities":{"people":[],"products":["Trikafta","Alyftrek","Trelegy","Evrysdi","Tremfya","Tysabri","Spinraza","Voranigo","Imbruvica","Xtandi","Nurtec ODT","Trodelvy"],"companies":[{"name":"Royalty Pharma plc","ticker":"RPRX","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T12:50:04.029Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"earnings-date-notice","issuerAuthored":true}},"durationMs":3852,"modelName":"glm-5.3-flashx"}}